Orchestra BioMed Holdings, Inc.
OBIO

$197.75 M
Marketcap
$5.20
Share price
Country
$0.16
Change (1 day)
$11.69
Year High
$4.22
Year Low
Categories

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

marketcap

P/B ratio for Orchestra BioMed Holdings, Inc. (OBIO)

P/B ratio as of 2023: 4.46

According to Orchestra BioMed Holdings, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.46. At the end of 2022 the company had a P/B ratio of 2.85.

P/B ratio history for Orchestra BioMed Holdings, Inc. from 2020 to 2023

P/B ratio at the end of each year

Year P/B ratio
2023 4.46
2022 2.85
2021 -2.89
2020 -5.40